The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation

Neurobiology of Aging

Volumn 22, Issue 6, 2001, Pages 923-930

  Potter, Huntington ^a,b   Wefes, Inge M ^a   Nilsson, Lars N G ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E; CHAPERONE; INTERLEUKIN 1; MESSENGER RNA; PEPTIDE; PROTEIN INHIBITOR;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; ASTROCYTE; BEHAVIOR; BIOCHEMISTRY; BRAIN; BRAIN REGION; CATALYSIS; CATALYST; CELL ACTIVATION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DISEASE MODEL; EPIDEMIOLOGICAL DATA; GENETIC POLYMORPHISM; GENETICS; HUMAN; IN VIVO STUDY; INFLAMMATION; MICROGLIA; NONHUMAN; PATHOGENESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RISK; RNA SYNTHESIS; SENILE PLAQUE; TRANSGENIC MOUSE;

ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; CATALYSIS; HUMANS; INFLAMMATION; MICE; MOLECULAR CHAPERONES; SERUM AMYLOID A PROTEIN;

EID: 0035696320     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00308-6     Document Type: Article

References (84)

1. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
2. Alzheimer's disease: Recent advances in understanding the brain amyloid deposits
3. The protease inhibitor α1-antichymotrypsin is associated solely with amyloid deposits containing the b-protein and is localized in specific cells of both normal and diseased brain
4. Über eine eigenartige erkrankung der hirnride
5. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study
6. Risk for Alzheimer's disease correlates with transcriptional activity of the apoE gene
7. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
8. Interaction among hepatocyte-stimulating factors, interleukin-1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma cells
9. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
10. A polymorphism in the regulatory region of ApoE associated with risk for Alzheimer's dementia
11. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
12. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
13. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1
14. Inflammatory mechanisms in Alzheimer's disease
15. α-antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population
16. α1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation
17. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease
18. Effects of NSAIDs on IL-1β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells
19. a1-antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro
20. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
21. Correlation between working memory deficits and Aβ deposits in transgenic APP+PS1 mice
22. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease
23. No genetic effect of α-1-antichymotrypsin in Alzheimer's disease
24. Apolipoproteins E receptors linking brain development and Alzheimer's disease
25. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
26. Absence of association of α1-antichymotrypsin polymorphisms with Alzheimer's disease: A report on autopsy-confirmed cases
27. Visualization of A beta 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ 42(43)
28. Alzheimer's peptide Aβ1-42 binds to two beta-sheets of α1-antichymotrypsin and transforms it from inhibitor to substrate
29. Rheumatoid arthritis and senile dementia of the Alzheimer's type
30. ApoE4-associated Alzheimer's disease risk is modified by a1-antichymotrypsin polymorphism
31. Developmental expression of α1-antichymotrypsin in brain may be related to astrogliosis
32. Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha1-antichymotrypsin gene in human astrocytes
33. A new polymorphism in the ApoE promoter associated with risk of developing Alzheimer's disease
34. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease
35. Monomeric and polymeric of α-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease
36. Serum α1-antichymotrypsin as a marker for Alzheimer-type dementia
37. Association of early-onset Alzheimer's disease with an interleukin-1 gene polymorphism
38. Is the binding of β-amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a β-strand insertion?
39. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
40. Promotion of the neurotoxicity of Alzheimer Aβ protein by the pathological chaperones ACT and apoE4: Inhibition by Aβ-related peptides and apoE2
41. IL-1 and TNF, but not IL-6, induce α-1 antichymotrypsin expression in the human astrocytoma cell line U373 MG
42. Anti-inflammatory drugs and Alzheimer disease
43. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
44. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
45. Microsatellite polymorphism of the α1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease
46. Astroglial expression of human α1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice
47. Lack of association between α-1-antichymotrypsin polymorphism and familial Alzheimer's disease, and allele epsilon 4 of apolipoprotein E
48. Implication of α1-antichymotrypsin polymorphism in familial Alzheimer's disease
49. Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer's disease
50. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
51. The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease
52. Effect of interleukin-6, dexamethazone, dbcAMP, and the A/T-signal peptide polymorphism on the expression of α-1 antichymotrypsin in astrocytes. Significance for Alzheimer's disease
53. α-1 antichymotrypsin promotes β-sheet amyloid plaque formation in a transgenic mouse model of Alzheimer's disease
54. Astrocytes in Alzheimer's disease gray matter express a1-antichymotrypsin mRNA
55. Apolipoprotein E polymorphism and Alzheimer's disease
56. The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease
57. a1-antichymotrypsin: The role of proteases and their inhibitors in the amyloid deposition of Alzheimer's disease and normal brain aging
58. The Alzheimer amyloid components a1-antichymotrypsin and β-protein form a stable complex in vitro
59. The potential of BACE inhibitors for Alzheimer's therapy
60. The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease
61. Beyond β-protein: New steps in the pathogenic pathway to Alzheimer's disease
62. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
63. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
64. Clinical trials of indomethacin in Alzheimer's disease
65. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease
66. Amyloid precursor protein is regulated by interleukin-1 at the translational level by 5′ untranslated region sequences
67. Results of a double-blind, placebo-controlled study of celebrid for the progression of Alzheimer's disease
68. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils
69. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease
70. Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: Correlation with neuritic plaque distribution
71. Apolipoprotein E and Alzheimer's disease
72. Apolipoprotein E: High affinity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
73. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease
74. α-1-antichymotrypsin bi-allele polymorphism, apolipoprotein E tri-allele polymorphism and genetic risk of Alzheimer's syndrome
75. Human plasma proteinase inhibitors
76. Genetic association of two chromosome 14 genes (presenilin 1 and α1-antichymotrypsin) with Alzheimer's disease
77. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation
78. Human apolipoprotein E: The Alzheimer's disease connection
79. Apolipoprotein E: A pathological chaperone in patients with cerebral and systemic amyloid
80. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro
81. Specific regional transcription of apolipoprotein E in human brain neurons
82. Association of the a1-antichymotrypsin polymorphism with cerebral amyloid angiopathy